WT1, a transcription factor isolated from Wilms' tumor, is highly expressed in various types of leukemia. 1 We have reported that measurement of WT1 expression levels by quantitative reverse transcription-polymerase chain reaction (WT1 assay) is useful for monitoring minimal residual disease (MRD) in almost all types of leukemia and in myelodysplastic syndrome. 1 The predictive value of quantitative WT1 assessment for relapse following allogeneic stem cell transplantation (SCT) in Philadelphia chromosome (Ph1)-positive leukemia has been reported to be poor in a series of 32 patients (26 CML in chronic phase). 2 According to these data, in four out of six patients who relapsed, an increase in WT1 from the background level was observed only at the time of or after relapse, and even in two patients in whom increasing WT1 levels were observed before the relapse, predictive value of WT1 could not be found because of low sensitivity (10 À2 ) of the WT1 assay. However, the data on kinetics of WT1 gene expression in patients with CML following allogeneic SCT are limited, and results should be interpreted with some caution.
WT1 has a characteristic expression profile that depends on the differentiation stage of leukemia: immature-type leukemia tends to express the WT1 gene at a highly increased level. Conversely, more differentiated acute myeloid leukemia (AML) subtypes such as AML-M5 were reported to express WT1 at lower levels. 1 Also, in in vitro experiments using leukemia cell lines, downregulation of the WT1 gene expression was observed during differentiation. 3 We showed in our previous study that patients with chronic phase (CP) CML expressed the WT1 gene at lower levels by one or two orders of magnitude than those in accelerated phase (AP) or blast crisis (BC), respectively. 1 In contrast, no difference in the amount of bcr-abl mRNA between CP and BC was observed. 4 Since the majority of CML cases that Uzunel et al 2 reported were in CP, the sensitivity of the WT1 assay for the transplant cohort in their study was expected not to be high. However, Cilloni et al 5 have found the WT1 assay to be useful for patients with CML in CP who were treated with imatinib. The reason for this discrepancy in findings is unclear.
There may have been several reasons for the low sensitivity of the WT1 assay in the study performed by Uzunel et al. 2 Firstly, they performed the WT1 assay using blood samples. We previously demonstrated that the WT1 expression level in blood was approximately 10 times lower than that in bone marrow (BM) regardless of the type of leukemia. 6 Secondly, they used the buffy coat of blood samples, whereas we have used mononuclear cells from BM or blood samples. Particularly in CP CML, the majority of cells in the buffy coat would consist of differentiated myeloid cells that may express bcr-abl mRNA but not WT1 mRNA. The use of mononuclear cell fractions would lead to an enrichment of immature cells from CML cell populations, possibly resulting in an increase in the sensitivity of the WT1 assay for MRD detection.
We recommend the use of mononuclear cells, and BM if possible, for monitoring MRD in patients with CML in CP who undergo allogeneic SCT. Despite the methodological problems in the study by Uzunel et al, 2 we agree with them that for patients with CML in CP who undergo allogeneic SCT, the WT1 assay may have a disadvantage over the MRD detection system based on quantifying bcrabl transcripts. However, for patients who have a relapse in AP or BC, the sensitivity of the WT1 assay will increase markedly, particularly with the use of BM samples.
Uzunel et al showed that the WT1 expression did not increase sufficiently at the time of relapse in two cases of Ph1 ALL. In contrast, when we analyzed MRD-positive samples from patients with acute-type leukemia (AML, ALL, CML in AP or BC) at different times after allogeneic SCT by using the real-time RT-PCR method, a strong correlation between the levels of gene expression of the WT1 and bcr-abl genes (r ¼ 0.924) was observed. 7 Furthermore, we showed that, in patients with Ph1 ALL, these two MRD markers mostly changed in parallel. 8 The majority of patients with acute-type leukemia express the WT1 gene at a sufficiently high level for monitoring MRD. However, the WT1 expression level in the leukemic cell population varies from case to case. 1 For successfully monitoring MRD by the WT1 assay, it is important to confirm that WT1 expression levels at the time of diagnosis are over 1 Â 10 À2 (the WT1 gene expression level in K562 cells being defined as 1.0).
There have been many reports showing that the WT1 gene is associated with leukemogenesis 9 or oncogenesis. Furthermore, we previously showed that the WT1 expression level increased significantly at relapse compared with that at the time of diagnosis. 10 These findings suggest that the WT1 expression level reflects some proliferative ability of leukemia cells. When Uzunel et al analyzed 23 paired PB and BM samples, the WT1 expression level in BM was higher by 1 log than that in PB, whereas no significant difference in the bcr-abl expression was found between PB and BM. 4 Their results also showed that WT1 expression is associated with the proliferation or immaturity of CML cells, while the amount of bcr-abl transcripts only reflects the burden of leukemia cells. Thus, simultaneously measuring the levels of WT1 and bcr-abl transcripts would make it possible to understand more deeply the behavior of the leukemia cells in each patient, enabling an early diagnosis of the progression from CP to AP or BC, even for patients who undergo transplantation in CP. 
